Startup Professionals Musings
OCTOBER 26, 2018
Today, with instant and pervasive Internet communication, you can sell your vision via blogging, crowdfunding, and videos before you spend big money building prototypes and pivoting as you learn. Marty Zwilling First published on CayenneConsulting on 10/10/2018.
Xconomy
AUGUST 16, 2019
billion in 2018, and Novartis reportedly knew but failed to report it to the FDA before the agency approved Zolgensma in May. We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7
Xconomy
NOVEMBER 11, 2016
—Oral arguments in the landmark patent fight over ownership of the gene editing technology CRISPR-Cas9 were set for Dec. Patent and Trademark Office. —Despite the patent fight, CRISPR work continues apace. —Despite the patent fight, CRISPR work continues apace. CRISPR DEVELOPMENTS. 6 at the U.S.
Expert insights. Personalized for you.
92 
Let's personalize your content